| Eun Hyea Godbold, | |
|
2525 Desales Ave, Chattanooga, TN 37404-1161 | |
| (423) 495-2525 | |
| Not Available |
| Full Name | Eun Hyea Godbold |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 4 Years |
| Location | 2525 Desales Ave, Chattanooga, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013540517 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 132493 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| American Anesthesiology Of Tennessee Pc | 9931001922 | 382 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
Flash floods have "worsened an already chronic humanitarian crisis caused by drought" in central Africa where aid agencies have warned that "10 million people are already facing severe food shortages, particularly in the landlocked countries of Chad and Niger, after a drought led to the failure of last year's crops," the Independent reports.
Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.
Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data.
› Verified 4 days ago
| Entity Name | American Anesthesiology Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609822998 PECOS PAC ID: 9931001922 Enrollment ID: O20040713001364 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
Flash floods have "worsened an already chronic humanitarian crisis caused by drought" in central Africa where aid agencies have warned that "10 million people are already facing severe food shortages, particularly in the landlocked countries of Chad and Niger, after a drought led to the failure of last year's crops," the Independent reports.
Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.
Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eun Hyea Godbold, 500 Dodds Ave, Chattanooga, TN 37404-3949 Ph: (941) 330-5620 | Eun Hyea Godbold, 2525 Desales Ave, Chattanooga, TN 37404-1161 Ph: (423) 495-2525 |
News Archive
ETView today announced that the Korean Food and Drug Administration ("KFDA") has granted pre-market clearance for VivaSight‐SL. With KFDA clearance, ETView plans to immediately initiate market launch of VivaSight‐SL. ETView also announced a distribution agreement with ChinooMTech Company.
Veloxis Pharmaceuticals and Athena Drug Delivery Solutions Pvt. Ltd. today announced an alliance whereby Athena will obtain exclusive rights in certain emerging market territories to manufacture and, with third parties, develop, register and commercialize Veloxis' AtorFen (Fenofibrate Atorvastatin fixed dose combination).
Flash floods have "worsened an already chronic humanitarian crisis caused by drought" in central Africa where aid agencies have warned that "10 million people are already facing severe food shortages, particularly in the landlocked countries of Chad and Niger, after a drought led to the failure of last year's crops," the Independent reports.
Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.
Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data.
› Verified 4 days ago
Megan A Spears, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-602-8400 Fax: 423-602-8401 | |
Mr. Edward Brian Hallock, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 975 E 3rd St, Chattanooga, TN 37403 Phone: 423-602-8400 Fax: 423-602-8401 | |
Amy T. Garner, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2341 Mccallie Ave, Suite 402, Chattanooga, TN 37404 Phone: 423-698-3309 Fax: 423-624-6355 | |
Christina Michelle Robinson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 979 E 3rd St Ste C235, Chattanooga, TN 37403 Phone: 423-602-8400 | |
Mrs. Julie D Baggett, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2341 Mccallie Ave, Suite 402, Chattanooga, TN 37404 Phone: 423-698-3309 Fax: 423-624-6355 | |
Susan L Battles, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 975 E Third St, Chattanooga, TN 37403 Phone: 423-778-7608 Fax: 423-778-2360 |